Full Press Release Details
dupixent dupilumab late breaking positive phase 3 data in chronic spontaneous urticaria to be presented at acaai.
REGN
dupixent dupilumab late breaking positive phase 3 data in chronic spontaneous urticaria to be presented at acaai
Key Takeaway: dupixent dupilumab late breaking positive phase 3 data in chronic spontaneous urticaria to be presented at acaai